“Demographics, Prior Therapies, and Reasons for Cemiplimab Treatment: Prospective CemiplimAb-rwlc Survivorship and Epidemiology (C.A.S.E.) Study in Patients with Advanced Cutaneous Squamous Cell Carcinoma” (2020) SKIN The Journal of Cutaneous Medicine, 4(6), p. s125. doi:10.25251/skin.4.supp.125.